Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDIR-NEOREC: Neoadjuvant Dostarlimab +/- RT in dMMR Rectal Cancer
NCT06762405Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Feb 2025
- Primary completion
- Sep 2030
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dostarlimab in rectal adenocarcinoma (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Treatment strategy failure rate at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT06762405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762405.